Legend Biotech Corporation research snapshot
LEGN AI stock analysis currently reads Legend Biotech as a cell therapy pioneer with one approved product (CARVYKTI for multiple myeloma, partnered with Johnson and Johnson), a growing pipeline, and a stock price that reflects both significant commercial potential and the inherent risk of a still-unprofitable biotech. At the July 12, 2026 cutoff, the latest verified close used here was $28.04, market capitalization was about $5.42 billion, and the main question was whether CARVYKTI revenue growth, pipeline catalysts, and a path to GAAP profitability can offset competitive pressure, capital needs, and dilution risk. This is informational research and not investment advice.
Current price
$28.04
Market cap
$5.42 billion
AI score
52 / 100
Rating
Innovative pipeline, pre-profit biotech risk
Trend status
Recovering from 52-week lows, above midpoint of range
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Legend Biotech develops cell therapies for cancer, with CARVYKTI (cilta-cel) as its lead approved product. Revenue comes from collaboration with Johnson and Johnson. The business model is high-margin if products succeed, but pre-profit and single-product-concentrated. | Medium |
| Moat | The moat comes from proprietary CAR-T technology, manufacturing expertise, J&J partnership providing commercial scale, and a growing IP portfolio. However, BCMA-directed competition (Tecvayli, Elrexfio) and potential next-gen modalities could narrow it. | Medium |
| Management | Management has shown strong scientific leadership and secured a major partnership with J&J. The June 2026 public offering raises questions about capital management timing, but the proceeds support pipeline expansion. | Medium |
| Financial trend | TTM revenue reached about $1.14 billion driven by CARVYKTI profit share, but net income was -$250.1 million. The company holds $834.6 million in cash with manageable debt. Path to profitability depends on revenue growth outpacing R&D spend. | Medium-high |
| Valuation | At roughly 4.85x TTM revenue and negative earnings, LEGN trades at a premium typical of pre-profit biotechs with approved products. Forward P/E of 232x implies investors expect profitability within 2-3 years. | Medium |
| Technical trend | LEGN traded at $28.04, above the midpoint of its $16.24 to $45.30 52-week range. The stock surged 42% on in vivo CAR-T data in June 2026 but has since pulled back, partly on a dilutive public offering. | Medium |
| Risk level | Key risks are single-product concentration, CARVYKTI competition, clinical trial setbacks, manufacturing complexity, regulatory changes, capital needs and dilution, and the binary nature of biotech investing. | Medium-high |
| AI confidence | Medium-high confidence for the business map, filing-backed financials, and major risk categories. Lower confidence for pipeline probability weighting and future stock returns. | Medium-high data confidence |
| Investment certainty | Low to medium certainty. Legend has a real approved product and strong partnership, but the stock outcome depends on execution and competitive dynamics that remain uncertain. | Low to medium |
LEGN AI stock forecast
The LEGN AI stock forecast uses scenario ranges around the $28.04 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires CARVYKTI label expansion, strong pipeline data, and a path to profitability. The base case assumes steady CARVYKTI growth with periodic dilution. The bearish case assumes competitive pressure or pipeline setbacks that increase capital needs.
$65 to $85
More likely if CARVYKTI expands into earlier multiple myeloma lines, the pipeline delivers positive clinical data (especially LB2501 in vivo CAR-T and LB5006 DLL3 program), the company reaches operating breakeven by 2028, and the market re-rates LEGN toward a higher revenue multiple.
$25 to $40
More likely if CARVYKTI revenue grows at a mid-teens pace, pipeline progress continues but without blockbuster surprises, occasional dilutive funding rounds occur, and the stock trades in line with pre-profit biotech peers with approved products.
$10 to $20
More likely if CARVYKTI faces significant competition from BCMA bispecifics, pipeline trials disappoint, manufacturing or regulatory setbacks occur, and the company needs repeated dilutive financing to fund operations.
LEGN AI technical analysis
LEGN AI technical analysis starts from the $28.04 July 6 close used for this July 12 static page. Public technical sources showed the stock trading above the midpoint of its 52-week range after a sharp June rally on in vivo CAR-T data, followed by a pullback after a public offering announcement. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $28.04 | Latest verified close used for this page as of the July 12, 2026 data cutoff (July 6 close from Yahoo Finance). |
| Near support | $24 to $26 | Support planning zone near the post-rally consolidation area. The stock found buying interest near these levels after the June offering announcement. |
| Secondary support | $18 to $20 | Area near the 52-week low of $16.24 from earlier in 2026. A sustained break below $18 would weaken the recovery setup significantly. |
| Near resistance | $32 to $35 | The area just below the pre-offering high. Breakout attempts would need volume confirmation and positive catalyst news. |
| Key resistance | $40 to $45 | The 52-week high area near $45.30. A move above $45 would signal a full recovery from the 2026 lows. |
| 50-day moving average | Estimated $26 to $28 | The stock was trading near its 50-day MA after the pullback. Holding above this level supports near-term momentum. |
| 200-day moving average | Estimated $22 to $24 | LEGN was above its 200-day MA after the June rally, supporting the medium-term recovery trend. |
| Momentum | Pulled back from overbought, RSI normalizing | The June rally pushed RSI into overbought territory. The subsequent pullback and offering have been normalizing momentum readings. |
| Volume | About 1.52 million shares (July 6) | Below the average of 2.79 million, suggesting the post-offering selling pressure may be easing. |
| Volatility | High, typical of biotech | Biotech stocks like LEGN can move 5-10% or more on single clinical data releases or regulatory news. Position sizing must account for this. |
| Invalidation | Close below $24, then $18 | A close below $24 would weaken the near-term recovery. A break below $18 would challenge the entire 2026 uptrend. |
LEGN AI trading strategy
The LEGN AI trading strategy is a rules-based framework, not personalized advice. Biotech stocks require special attention to binary catalyst risk, so position sizing and catalyst awareness matter more than technical patterns.
Monitor LEGN around known catalysts: CARVYKTI label expansion decisions, clinical data readouts (LB2501, LB5006), earnings reports with CARVYKTI sales updates, and regulatory filings. Enter only when the risk/reward of the specific catalyst can be assessed.
Biotech binary events can move the stock 20-40%. Define maximum loss before the event and do not add to a position after a negative catalyst.
Look for LEGN to hold above the 50-day MA ($26-28 zone) and reclaim the $32-35 resistance area on above-average volume before treating momentum as confirmed.
A failed bounce below $24 should reduce confidence. Biotech trends can reverse quickly on news, so trailing stops are important.
Track quarterly CARVYKTI revenue growth, J&J collaboration updates, pipeline clinical data, cash runway, share count changes (dilution), and competitive landscape developments.
Lower the rating if CARVYKTI growth decelerates meaningfully, the pipeline suffers setbacks, or the company needs large dilutive financing at depressed prices.
Investment research summary
Legend Biotech develops and commercializes cell therapies for cancer. CARVYKTI, its lead product, is a CAR-T therapy for multiple myeloma marketed through a global partnership with Johnson and Johnson.
The moat is cell therapy manufacturing expertise, proprietary CAR-T technology, J&J partnership providing commercial infrastructure, and an early lead in BCMA-directed CAR-T. Competition from bispecific antibodies and next-gen cell therapies is the main threat.
The thesis can fail if CARVYKTI adoption plateaus, J&J partnership economics shift, competitive BCMA therapies erode market share, pipeline products fail, manufacturing yields disappoint, or the company runs out of cash without achieving profitability.
Founder and CEO Dr. Ying Huang leads a scientifically driven team. The J&J partnership reflects strong deal-making. The June 2026 public offering was prudent for pipeline funding but dilutive. Succession depth and commercialization experience remain monitoring items.
Cell therapy is one of the fastest-growing areas in oncology, with CAR-T moving into earlier lines of therapy and expanding into new indications. Legend is positioned in the BCMA space with potential pipeline expansion into solid tumors.
At roughly 4.85x TTM revenue and not yet GAAP profitable, the stock requires confidence in CARVYKTI growth and pipeline execution. Without positive clinical catalysts or profitability milestones, the margin of safety is limited.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| LEGN price | $28.04 close on July 6, 2026 | Yahoo Finance quote snapshot | July 12, 2026 |
| Market capitalization | $5.42 billion, verified as $28.04 x 193,437,946 shares | financial_rigor.py market cap verification and Yahoo Finance | July 12, 2026 |
| TTM revenue | $1.14 billion | Yahoo Finance financials summary | July 12, 2026 |
| TTM net income | -$250.1 million | Yahoo Finance financials summary | July 12, 2026 |
| TTM EPS | -$1.38 | Yahoo Finance statistics | July 12, 2026 |
| Cash and equivalents | $834.6 million (most recent quarter) | Yahoo Finance balance sheet summary | July 12, 2026 |
| Total debt / equity | 40.23% | Yahoo Finance statistics | July 12, 2026 |
| Enterprise value | $5.34 billion | Yahoo Finance statistics | July 12, 2026 |
| Forward P/E | 232.56x | Yahoo Finance key statistics | July 12, 2026 |
| Price / Sales (TTM) | 4.85x | Yahoo Finance key statistics, verified by financial_rigor.py | July 12, 2026 |
| Price / Book (MRQ) | 5.98x, verified as $28.04 / $4.69 BVPS | financial_rigor.py valuation verification | July 12, 2026 |
| Analyst 1-year price target | $57.24 average | Yahoo Finance analyst estimates | July 12, 2026 |
| 52-week range | $16.24 to $45.30 | Yahoo Finance summary | July 12, 2026 |
This LEGN AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. Biotech stocks carry elevated risk of binary outcomes that no scenario analysis can fully capture.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
